Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction

Toxicology

Volumn 155, Issue 1-3, 2000, Pages 37-44

  Xi, Lei ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemia reperfusion; Monophosphoryl lipid A; Myocardial infarction; Nitric oxide; Pharmacological preconditioning; Signal transduction

Indexed keywords

GLYCOLIPID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHORYL LIPID A; RC 552; S METHYLPSEUDOTHIOUREA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INDUCTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TREATMENT OUTCOME;

NEGIBACTERIA;

EID: 0034735906     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(00)00275-4     Document Type: Article

References (43)

1. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial
2. Myocardial protection after monophosphoryl lipid A: Studies of delayed anti-ischaemic properties in rabbit heart
3. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide
4. Pharmacological preconditioning of primary rat cardiac myocytes by FK506
5. Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury
6. Myocardial ischemia/reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide
7. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene
8. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance
9. Signal transduction mechanisms involving nitric oxide
10. Pharmacological evidence that inducible nitric oxide synthase is a mediator of delayed preconditioning
11. ATP channel
12. Chemical synthesis of the major constituents of Salmonella minnesota monophosphoryl lipid A
13. Induction of tumor necrosis factor, IFN-γ, and acute lethality in mice by toxic and non-toxic forms of lipid A
14. Nitric oxide synthases in mammals
15. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia
16. Cardiac stress protein elevation 24 h after brief ischemia or heat stress is associated with resistance to myocardial infarction
17. Nitric oxide signaling in ischemic heart
18. Oxidative stress adaptation improves postischemic ventricular recovery
19. ATP channels mediate late preconditioning against infarction produced by monophosphoryl lipid A
20. + channel of vascular smooth muscle cells
21. Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury
22. ATP channel induces early and delayed cardioprotective effects: Role of nitric oxide
23. Myocardial preconditioning: Basic concepts and potential mechanisms
24. Tyrosine phosphorylation of inducible nitric oxide synthase: Implications for potential post-translational regulation
25. Possibilities for the pharmacological exploitation of ischemic preconditioning
26. Pharmacological preconditioning of ischemic heart disease by low dose dipyridamole
27. Cardioprotection with ischemic preconditioning and MLA: Role of adenosine-regulating enzymes?
28. Purification and structure determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium
29. Monophosphoryl lipid A obtained from lipopolysaccharide of Salmonella minnesota R595
30. Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischemia and reperfusion in rats: Role of nitric oxide
31. Delayed endothelial protective effects of monophosphoryl lipid A after myocardial ischemia and reperfusion in rats
32. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide
33. Monophosphoryl lipid A reduces both arrhythmia severity and infarct size in a rat model of ischemia
34. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase
35. Preconditioning of rat heart with monophosphoryl lipid A: A role of nitric oxide
36. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing
37. Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: Evidence from pharmacological inhibition and gene knockout mice
38. Glycolipid RC552 induces delayed preconditioning-like effect via iNOS-dependent pathway in mice
39. Myocardial protection by monophosphoryl lipid A: Potential mechanisms
40. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog
41. Ischemic preconditioning: Present position and future directions
42. Monophosphoryl lipid A induces pharmacologic 'preconditioning' in rabbit hearts without concomitant expression of 70-kDa heat shock protein
43. Role of inducible nitric oxide synthase in pharmacological 'preconditioning' with monophosphoryl lipid A